Cargando…

Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections

Invasive fungal infections (IFIs) are associated with high mortality rates and timely appropriate antifungal therapy is essential for good outcomes. Emerging antifungal resistance among Candida and Aspergillus spp., the major causes of IFI, is concerning and has led to the increasing incorporation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamoth, Frederic, Lewis, Russell E., Kontoyiannis, Dimitrios P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823995/
https://www.ncbi.nlm.nih.gov/pubmed/33396870
http://dx.doi.org/10.3390/jof7010017
_version_ 1783639969354481664
author Lamoth, Frederic
Lewis, Russell E.
Kontoyiannis, Dimitrios P.
author_facet Lamoth, Frederic
Lewis, Russell E.
Kontoyiannis, Dimitrios P.
author_sort Lamoth, Frederic
collection PubMed
description Invasive fungal infections (IFIs) are associated with high mortality rates and timely appropriate antifungal therapy is essential for good outcomes. Emerging antifungal resistance among Candida and Aspergillus spp., the major causes of IFI, is concerning and has led to the increasing incorporation of in vitro antifungal susceptibility testing (AST) to guide clinical decisions. However, the interpretation of AST results and their contribution to management of IFIs remains a matter of debate. Specifically, the utility of AST is limited by the delay in obtaining results and the lack of pharmacodynamic correlation between minimal inhibitory concentration (MIC) values and clinical outcome, particularly for molds. Clinical breakpoints for Candida spp. have been substantially revised over time and appear to be reliable for the detection of azole and echinocandin resistance and for outcome prediction, especially for non-neutropenic patients with candidemia. However, data are lacking for neutropenic patients with invasive candidiasis and some non-albicans Candida spp. (notably emerging Candida auris). For Aspergillus spp., AST is not routinely performed, but may be indicated according to the epidemiological context in the setting of emerging azole resistance among A. fumigatus. For non-Aspergillus molds (e.g., Mucorales, Fusarium or Scedosporium spp.), AST is not routinely recommended as interpretive criteria are lacking and many confounders, mainly host factors, seem to play a predominant role in responses to antifungal therapy. This review provides an overview of the pre-clinical and clinical pharmacodynamic data, which constitute the rationale for the use and interpretation of AST testing of yeasts and molds in clinical practice.
format Online
Article
Text
id pubmed-7823995
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78239952021-01-24 Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections Lamoth, Frederic Lewis, Russell E. Kontoyiannis, Dimitrios P. J Fungi (Basel) Review Invasive fungal infections (IFIs) are associated with high mortality rates and timely appropriate antifungal therapy is essential for good outcomes. Emerging antifungal resistance among Candida and Aspergillus spp., the major causes of IFI, is concerning and has led to the increasing incorporation of in vitro antifungal susceptibility testing (AST) to guide clinical decisions. However, the interpretation of AST results and their contribution to management of IFIs remains a matter of debate. Specifically, the utility of AST is limited by the delay in obtaining results and the lack of pharmacodynamic correlation between minimal inhibitory concentration (MIC) values and clinical outcome, particularly for molds. Clinical breakpoints for Candida spp. have been substantially revised over time and appear to be reliable for the detection of azole and echinocandin resistance and for outcome prediction, especially for non-neutropenic patients with candidemia. However, data are lacking for neutropenic patients with invasive candidiasis and some non-albicans Candida spp. (notably emerging Candida auris). For Aspergillus spp., AST is not routinely performed, but may be indicated according to the epidemiological context in the setting of emerging azole resistance among A. fumigatus. For non-Aspergillus molds (e.g., Mucorales, Fusarium or Scedosporium spp.), AST is not routinely recommended as interpretive criteria are lacking and many confounders, mainly host factors, seem to play a predominant role in responses to antifungal therapy. This review provides an overview of the pre-clinical and clinical pharmacodynamic data, which constitute the rationale for the use and interpretation of AST testing of yeasts and molds in clinical practice. MDPI 2020-12-30 /pmc/articles/PMC7823995/ /pubmed/33396870 http://dx.doi.org/10.3390/jof7010017 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lamoth, Frederic
Lewis, Russell E.
Kontoyiannis, Dimitrios P.
Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections
title Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections
title_full Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections
title_fullStr Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections
title_full_unstemmed Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections
title_short Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections
title_sort role and interpretation of antifungal susceptibility testing for the management of invasive fungal infections
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823995/
https://www.ncbi.nlm.nih.gov/pubmed/33396870
http://dx.doi.org/10.3390/jof7010017
work_keys_str_mv AT lamothfrederic roleandinterpretationofantifungalsusceptibilitytestingforthemanagementofinvasivefungalinfections
AT lewisrusselle roleandinterpretationofantifungalsusceptibilitytestingforthemanagementofinvasivefungalinfections
AT kontoyiannisdimitriosp roleandinterpretationofantifungalsusceptibilitytestingforthemanagementofinvasivefungalinfections